Logo

MiRxes

Singapore's Mirxes Inks Agreements for Cancer Early Detection Tests in China, Indonesia

Mirxes signed an MOU to scale up manufacturing of its tests in China and expanded an existing commercialization partnership in Indonesia.

In Brief This Week: MiRxes, Oncocyte, OpGen, Biodesix, Element Biosciences, More

News items for the week of Aug. 7, 2023

MiRxes Gets $50M in Series D Funding, Applies to Hong Kong Limited Stock Exchange

The firm plans to use the investment to scale adoption and penetration of its flagship stomach cancer blood test in Asia-Pacific markets and to develop other assays.

MiRxes, PT Elion to Develop Cancer Tests for Indonesian Population

As part of the arrangement, PT Elion will validate MiRxes' microRNA-based tests for stomach and lung cancer in an Indonesian cohort.

MiRxes Launches Study for Pulmonary Hypertension Biomarkers in Asian Populations

The Singapore-based biotech company will evaluate its miRNA biomarker assay for early detection of pulmonary hypertension as part of the SPHERE study.